A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection
A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection
复制标题
DOI：
10.1080/14656566.2017.1282459
复制
发表时间：
2017-03
影响因子：
3.2
通讯作者：
I. Weisberg;I. Jacobson
中科院分区：
文献类型：
--
作者：
I. Weisberg;I. Jacobson
摘要引言：丙型肝炎病毒（HCV）感染全球近1.7亿人，是进行性肝损伤、肝硬化和肝细胞癌的主要原因。治愈性疗法历来依赖于基于干扰素的治疗，并受到显著毒性和不良反应率的限制，特别是在既往治疗失败和晚期肝纤维化的患者中。针对HCV病毒生命周期中关键步骤的直接作用抗病毒（DAA）药物的最近出现，通过提供高效且耐受性良好的无干扰素治疗，改变了HCV治疗的前景。然而，目前的治疗是基因型特异性的，并且在不太流行的HCV变体中具有可变的疗效。涵盖的领域：本综述涵盖了索非布韦/维帕他韦（SOF/VEL）的临床前和临床开发，这是一种无干扰素，每日一次，用于治疗慢性丙型肝炎病毒（HCV）感染的泛基因型治疗。包括2014年至2016年9月的所有相关文献。专家意见：SOF/VEL提供了一个单一的片剂，干扰素和利巴韦林免费治疗的承诺，具有极高的疗效与慢性丙型肝炎病毒感染的人，无论基因型，亚型，治疗史或纤维化状态。预计它将在全球范围内发挥重要作用，为人类健康提供治疗手段，以应对这一无处不在的威胁。
ABSTRACT Introduction: Hepatitis C virus (HCV) infects nearly 170 million people worldwide and is a leading cause of progressive liver damage, cirrhosis, and hepatocellular carcinoma. Curative therapies have historically relied on interferon-based treatments and were limited by significant toxicity and poor response rates, particularly among patients with prior treatment failure and advanced hepatic fibrosis. The recent advent of direct acting antiviral (DAA) agents which target key steps in the HCV viral life cycle has transformed the landscape of HCV treatment by offering highly effective and well tolerated interferon-free treatments. However, current therapies are genotype-specific and have variable efficacy amongst less prevalent HCV variants. Areas covered: This review covers the preclinical and clinical development of sofosbuvir/velpatasvir (SOF/VEL), an interferon-free, once daily, pangenotypic treatment for the treatment of chronic hepatitis C virus (HCV) infection. All relevant literature from 2014 through September of 2016 is included. Expert opinion: SOF/VEL offers the promise of a single tablet, interferon- and ribavirin-free treatment that has extremely high efficacy in persons with chronic HCV infection regardless of genotype, subtype, treatment history or fibrosis status. It is expected to play a major role on a global scale in the therapeutic armamentarium against this ubiquitous threat to human health.